Clinical trials: Relapsed or Refractory T-cell Lymphomas
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Phase IIa study to estimate the efficacy of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as CART-19 or CTL019…
- Trial name
- NCT02030834
- Testing
- CART-19
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
The purpose of this study is to test whether radiation therapy given before standard CAR T cell therapy is a safe and effective treatment for people with relapsed and refractory B cell lymphoma.
- Conditions
- Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
- Trial name
- NCT05574114
- Testing
- Bridging radiotherapy (BRT), Conditioning chemotherapy, CAR T-cell product
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy for…
- Conditions
- Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
- Trial name
- NCT05075603
- Testing
- Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- NeoImmuneTech
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Lymphomas, B-cell Lymphomas
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
- Trial name
- NCT05773040
- Testing
- JV-213, Leukapheresis
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Lymphoma, T-Cell
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
This study is an open and prospective clinical study, taking patients with relapsed or refractory CD7+ lymphoma as the test subjects, in order to evaluate the safety and efficacy of Senl-T7 CAR-T for patients with CD7+ lymphoma.
- Trial name
- NCT04928105
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Relapsed or Refractory B Cell Leukemia and Lymphoma
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
- Trial name
- NCT06834529
- Testing
- CAR2219-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
B-cell Acute Lymphoblastic Leukemia, Lymphoblastic B-Cell Lymphoma
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
- Trial name
- NCT05333302
- Testing
- CD19 CAR-T-cells, Tocilizumab
- Where
- Belarus
- Volunteers
- 10 people
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
B-Cell Acute Lymphoblastic Leukemia
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT07429461
- Testing
- SYNCAR-100 Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang University
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
- Trial name
- NCT04109482
- Testing
- MB-102, Fludarabine, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mustang Bio
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor in patients with relapsed or refractory B-Cell Non-Hodgkin…
- Trial name
- NCT02134262
- Testing
- Cyclophosphamide or Bendamustine, Dose Level -1, Dose Level 1
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Jichi Medical University
CLL/SLL, NHL
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
- Conditions
- CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05665062
- Testing
- SYNCAR-001, STK-009, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Synthekine
Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
- Trial name
- NCT03808610
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
This study is an open label, multicenter phase 2 study. The primary objective of the study is to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for relapsed or refractory peripheral T-cell…
- Trial name
- NCT03496779
- Testing
- Brentuximab Vedotin - induction, Gemcitabine, Brentuximab Vedotin - maintenance
- Where
- 39 sites in Belgium, France
- Volunteers
- 71 people
- Sponsor
- The Lymphoma Academic Research Organisation
Peripheral T-cell Lymphoma
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
- Trial name
- NCT01689220
- Testing
- SP-02L (darinaparsin for injection)
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Solasia Pharma K.K.
Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma
Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma
This study is to evaluate the efficacy and safety of lenalidomide maintenance therapy in patients with T-cell lymphoma who have undergone more than one treatment or relapsed after treatment and who acquired a response of more…
- Trial name
- Lemon-T (NCT03730740)
- Testing
- Lenalidomide 25mg
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Samsung Medical Center
B-cell Acute Lymphoblastic Leukemia
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
- Trial name
- NCT06559189
- Testing
- CD19x22 CAR T
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
- Conditions
- Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00100152
- Testing
- MK0752, (Notch Inhibitor)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00182650
- Testing
- aldesleukin, rituximab, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center